Objective To compare the clinical efficacies of high-intensity focused ultrasound (HIFU) and laparoscopic myomectomy (LM) in the treatment of uterine fibroids and their effects on patients' quality of life.
Introduction
Uterine fibroid is a common disease in women of childbearing age, accounting for 52% of benign tumours in gynaecology. 1 About 30% of patients with uterine fibroids presented clinical symptoms 2 such as irregular vaginal bleeding, anaemia and other clinical symptoms triggered by compression of the surrounding organs in patients with a large fibroid mass, compromising the quality of life in female patients. The treatment of uterine fibroids is surgery-based, 3 and conventional surgeries include transabdominal hysterectomy and myomectomy, which are unacceptable to some patients due to severe trauma and slow recovery. With the development of medical technology, minimally invasive and non-invasive technologies, such as total laparoscopic hysterectomy, hysteromyomectomy, uterine arterial embolisation, have become increasingly popular with patients. All these treatments are characterised by minimal invasion, uterine preservation, and quick postoperative recovery, all of which have greatly improved patients' life quality.
Recently, HIFU therapy has been widely applied in the treatment of uterine fibroids. Researches have shown that a non-perfused volume ratio of more than 70% of tumour size could be a definite indicator of the long-term efficacy of HIFU. 4, 5 But among patients who demand preservation of the uterus, there has been no comparative study of HIFU therapy and LM therapy in terms of benefits for patients and scale of pain. To provide solid evidence for clinical decisions, this study intended to analyse retrospectively the effectiveness and adverse effects of HIFU and LM in patients with uterine fibroids in our hospital to compare the effects of the two therapies on patients' quality of life.
Materials and methods

Subjects
A total of 187 patients with uterine fibroids received minimally invasive and non-invasive treatment in our hospital, of whom 21 were excluded for the combination of ovarian cyst and other gynaecological diseases. The 166 patients who met the inclusion criteria underwent LM treatment or HIFU treatment, respectively.
Inclusion criteria included: (1) childbearing women aged over 20; (2) intermural fibroids; (3) fewer than three fibroids; (4) maximum diameter <10 cm.
Exclusion criteria included: (1) submucosal fibroids; (2) subserousal fibroids with pedicle; (3) women during pregnancy; (4) suspected or confirmed malignant tumour; (5) concomitant ovarian cyst or acute pelvic inflammatory disease; (6) administration of hormonal drugs in the past 3 months.
Thorough communication with patients was conducted before the procedure. Treatment was determined in accordance with patient preferences and surgical indications. A written informed consent was obtained from all participants. Ninety-nine patients received HIFU ablation in the Haifu Unit after the exclusion of operative contraindications. The therapeutic procedure was performed using the model JC200 focused ultrasound tumor therapeutic system (Chongqing Haifu Medical Technology Co., Ltd., Chongqing, China) under real-time ultrasound guidance. Sixtyseven patients received LM.
Efficacy evaluation
Follow-up visits were conducted at 1 day, 6 months and 1 year after treatment, respectively. Major adverse effects and complications were recorded during and after the operation, including time of leaving bed after operation, time of feeding, the presence of postoperative fever, and blood loss volume during operation. The duration of the hospital stay was recorded and treatment effectiveness was evaluated by ultrasonography and MRI. All patients completed the SF-36 questionnaire on quality of life.
In the HIFU group, effectiveness was marked by shrinkage of fibroids, reduced blood flow of fibroids or improvement of clinical symptoms; ineffectiveness was manifested by enlargement of fibroids, increased internal blood flow, and no improvement of clinical symptoms.
In the LM group, effectiveness was marked by removal of a large part of the fibroids, improvement of symptoms; ineffectiveness was manifested by partial removal of fibroids, recurrence of fibroid indicated by colour Doppler ultrasound within 6 months, and non-apparent improvement of clinical symptoms.
Statistical methods
All analyses were performed with SPSS (17.0 version). Pairwise comparison of baseline characteristics in subjects was conducted by means of independent-samples t-test. Statistical significance for difference was defined as P < 0.05. The effectiveness of the two groups was compared using Chisquare test.
Results
Perioperative comparisons
The HIFU group had no intraoperative blood loss, fewer postoperative complications, and significantly lower postoperative pain scores compared with the LM group (P < 0.05). The temperature of eight patients in the LM group at 24-48 hours after surgery was over 38°C. Without special treatment, temperature automatically fell to normal 48 hours after surgery. Two patients in the HIFU group showed skin blisters around the treated region and one patient experienced numbness and discomfort in bilateral lower limbs, but symptoms subsided within 1 week. No severe complications occurred in either group. No significant differences in surgery time between the LM group and the HIFU group were observed (P > 0.05). The postoperative activity time, postoperative feeding time, and hospital stays in the HIFU group were significantly shorter than those in the LM group, the difference being statistically significant (P < 0.05) ( Table 1) .
Efficacy comparison
Postoperative follow-up visits at 6 and 12 months in the LM group showed substantial symptom improvement in 52 patients and partial symptom improvement in 13, a total effective rate of 97%. In the HIFU group, 6 months after treatment, 62 patients showed a substantial shrinkage of fibroid size and complete symptom relief, and 36 patients showed shrinkage of fibroid size and partial relief, a total effective rate of 99%. Twelve months after HIFU, the total effective rate reached 99%; in one ineffective case, laparoscopic myomectomy was performed 8 months later. There was no significant difference in the effective rate between two groups (P > 0.05) ( Table 2) .
Discussion
Uterine fibroids are a type of ovarian steroid hormonedependent benign tumour in the female reproductive system. 6 The goal of treatment for uterine fibroids is to control symptoms and relieve patients' psychological pressure. There are various treatments for uterine fibroid, each with its own advantages and indications. Clinical decisions hinge on, among other factors, patient ages, reproduction wishes, symptoms, and the location, size, and number of fibroids.
Laparoscopic myomectomy therapy has been well established and confirmed to be safe and effective in uterineconserving treatment of uterine fibroids. 7 HIFU is a new technology characterised by its non-invasiveness. The mechanism of HIFU treatment is to focus ultrasound wave, with its good ability of tissue penetration, on the target tumour, which leads to an instant temperature rise to 70-100°C, causing coagulative necrosis of tumour tissues. Postoperative necrotic lesions after treatment were absorbed by the body or turned into fibrosis, thus achieving treatment goal.
Although many studies have indicated the safety and effectiveness of HIFU in the treatment of uterine fibroids, there has been no study comparing HIFU therapy and LM therapy. The results derived from this study showed that the excellence rate, effective rate, and total effective rate in the HIFU group after treatment were 63% (62/99), 36% (36/ 99), and 99% (98/99), respectively. The total effective rate in the LM group was 97% (65/67). There was no significant difference in efficacy between two groups (v 2 = 6.063, P > 0.05). Results indicated that the definite efficacy of HIFU therapy is equivalent to that of LM therapy.
The common complications of HIFU in the treatment of uterine fibroid include skin burn in the abdominal wall, numbness or pain in lower limbs caused by lumbosacral nerve irritability and damage. 8, 9 Skin burn in the abdominal wall was mostly seen in patients with abdominal scarring. Poor skin preparation may increase the risk of skin burn during HIFU. The heat radiation of HIFU therapy could stimulate adjacent nerves and cause corresponding symptoms because some fibroids are adjacent to lumbosacral nerves. However, these complications can be prevented by taking the following precautions: good communication with patients prior to the procedure, strict preparation for degreasing and degassing of the skin, checking skin during HIFU treatment, and observation of various patient reactions in during operation.
This study also demonstrated that patients treated with HIFU reported fewer complications, shorter hospital stays, lower postoperative pain, and faster recovery, which enabled them to return to routine activities 1 day after HIFU, thereby greatly reducing the aftermath of the operation and increasing patients' quality of life. HIFU, with built-in high-resolution ultrasound imaging, could detect and ablate small lesions when treating multiple fibroids of the uterus, especially multiple small fibroids; whereas these small lesions may remain untreated in the LM treatment. Moreover, HIFU therapy may damage the hormone receptor on the fibroid membrane, lowering its sensitivity to hormone and preventing the growth and relapse of uterine fibroid. 10, 11 Thanks to these unique advantages plus optimisation of indications for HIFU treatment, HIFU therapy will have a broader application in the treatment of uterine fibroids. 
Conclusions
High-intensity focused ultrasound is a safe, effective therapy in the treatment of uterine fibroids. Compared with LM therapy, HIFU has fewer side effects on patients, requires no general anaesthesia or intra-operative blood transfusion, and leads to quick postoperative recovery, all of which can effectively improve quality of life of patients with uterine fibroids and makes HIFU a widely applicable treatment modality. However, this study has its limitations due to its small sample size and retrospective nature. Multi-centre, large-sample prospective studies are necessary to obtain further convincing results for establishing this new treatment as the standard of care for uterine fibroids.
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